Earnshaw S, Brogan AJ, Brodtkorb T-H, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2021 Virtual ISPOR Short Course Program; December 6, 2021. Previously presented at the ISPOR 20th Annual International Meeting.
Earnshaw S, Carlsen J, McDade C, Le Coent V, Sable B, Dassaud J. Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing given an updated reimbursement approach. Presented at the AABB Virtual 2021 Annual Meeting; October 17, 2021.
Earnshaw S, Beyhaghi H, McDade C, Purser M, Marriott R, Daane L, Le Coent V, Yang J, Toback S. Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States. Transfusion. 2021 Oct;61(10):2885-97. doi: 10.1111/trf.16589
Bryan A, Earnshaw SR, McDade C, Ines M, Micallef C, Enoch DA. Economic evaluation of diagnostic-driven versus empirical treatment strategies in high-risk immunocompromised patients with suspected Aspergillus infection. Poster presented at the 2021 Virtual 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); July 9, 2021.
Mauskopf JA, Mullins CD, Earnshaw SR. Budget impact analysis: a 6-step approach. Presented at the Saudi Ministry of Health; April 2021.
Earnshaw SR, Mauskopf JA, Mullins CD, Brodtkorb T-H. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Virtual Short Course Progam; February 3, 2021. Previously presented at the 2015 ISPOR 18th Annual European Congress.
Earnshaw S, McDade C, Marriott R, Daane L, Le Coent V, Yang J. Costs and outcomes associated with large volume delayed sampling and pathogen reduction technology processing. Poster presented at the 2021 31st International Society of Blood Transfusion (ISBT) Virtual Conference; June 2, 2021. [abstract] Vox Sang. 2021; 116(Suppl 1):167.
Earnshaw SR, McDade CL, Graham CN, Spears J, Kessler C. Economic comparison of treating hemophilia patients who have developed inhibitors via immune tolerance induction versus prophylaxis and on-demand treatment with bypassing agents. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):422. doi: 10.1182/blood.V122.21.422.422
Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013 Oct;28(11):1483-91.
Wilson MR, Gutierrez B, Offord S, Zhao C, Beillat M, Eramo A, Earnshaw SR. Total healthcare cost-offset associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Poster presented at the US Psychiatric & Mental Health Congress; September 2013.
Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.
Earnshaw SR, Brogan AJ. Markov model toolkit: concepts, assumptions and examples. Presented at the 2013 ISPOR Distance Learning Program; April 2013.
Barnes R, Earnshaw SR, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade CL. Economic comparison of empirical versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infection. Poster presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases; April 2013.